Research

AI-Designed Drugs in Clinical Trials, November 2026

Named compounds from AI drug discovery companies, with phase and status read from ClinicalTrials.gov on November 13, 2026. Two are in Phase 3: Insilico rentosertib and Generate GB-0895. None is approved.

By Ramanath, CTO & Co-Founder at Presenc AI · Last updated: November 2026

This page lists 15 named compounds from companies that describe their discovery platforms as AI-driven, with the phase and status shown on ClinicalTrials.gov on November 13, 2026. Two are in Phase 3: rentosertib from Insilico Medicine and GB-0895 from Generate Biomedicines. No regulator has approved a drug from this list. A trial phase says how far testing has gone. It does not say that a drug works.

Phase 3

CompoundCompanyConditionRegistry IDStatusStart datePlanned enrolment
Rentosertib (INS018_055)Insilico MedicineIdiopathic pulmonary fibrosisNCT07687459RecruitingSeptember 9, 2026320
GB-0895, SOLAIRIA-1Generate BiomedicinesSevere asthmaNCT07276724RecruitingDecember 3, 2025786
GB-0895, SOLAIRIA-2Generate BiomedicinesSevere asthmaNCT07359846RecruitingJanuary 20, 2026786

Rentosertib. Insilico announced "the initiation" of the Phase 3 trial on July 7, 2026. The registry shows an actual start date of September 9, 2026. We found no source explaining the gap, and the release did not say a patient had been dosed. The trial is randomised, double-blind and placebo-controlled, at 47 centres in China, with once-daily dosing for 52 weeks. Insilico says the target was identified with its AI software and the molecule designed with generative AI. The registry lists primary completion as estimated for October 30, 2029.

GB-0895. An antibody against TSLP. Generate says it is the first biologic engineered with an AI-enabled platform to reach Phase 3. That is the company's own claim.

Phase 1 and Phase 2

CompoundCompanyConditionPhaseRegistry IDStatus
ISM5411Insilico MedicineUlcerative colitis2NCT07265570Recruiting
Rentosertib, second Phase 2 studyInsilico MedicineIdiopathic pulmonary fibrosis2NCT05975983Recruiting
ISM3412Insilico MedicineAdvanced solid tumours1/2NCT06414460Recruiting
ISM6331Insilico MedicineMesothelioma and other solid tumours1/2NCT06566079Recruiting
ISM8207Insilico MedicineSolid tumours and B-cell lymphoma1NCT06445517Recruiting
ISM8969Insilico MedicineHealthy and obese adult volunteers1NCT07581431Recruiting, started June 15, 2026
ISM9528Insilico MedicineHealthy volunteers1NCT07932041Recruiting, started October 29, 2026
ISM5939Insilico MedicineAdvanced solid tumours1NCT06724042Not yet recruiting
XL309 (ISM3091)Exelixis, licensed from InsilicoAdvanced solid tumours1NCT05932862Active, not recruiting
REC-4881RecursionFamilial adenomatous polyposis1/2NCT05552755Recruiting
REC-617 (GTAEXS617)Recursion, through its Exscientia unitAdvanced solid tumours1/2NCT05985655Recruiting
REC-1245RecursionAdvanced cancers and lymphomas1/2NCT06678659Recruiting
REC-994RecursionCerebral cavernous malformation2NCT05085561Completed
IAM1363Iambic TherapeuticsHER2 cancers1/1bNCT06253871Recruiting

A second Recursion study of REC-4881, in cancers with AXIN1 or APC mutations (NCT06005974), is listed as terminated.

Not on the List, and Why

  • Isomorphic Labs. No trial is registered under its name. See Isomorphic Labs funding and clinical trial status.
  • Anthropic. Its own programmes are preclinical. The company says a first trial could start as soon as late 2028. See Anthropic life sciences partnerships.
  • Zasocitinib (TAK-279), Takeda. The FDA accepted its application for plaque psoriasis under priority review, Takeda said on September 14, 2026, with a decision date in the first quarter of 2027. It is sometimes described as computationally designed. Whether that counts as AI-designed is disputed, so we have left it out of the tables.

How Many Are There in Total?

Counts differ because there is no agreed definition of "AI-designed". Two figures circulate in 2026 coverage and we could trace neither to a primary source.

  • An analysis presented at the ASCO meeting in 2026 counted 117 AI-enabled assets from 63 companies that had entered human trials, of which 60 had completed Phase 1 and 8 had completed Phase 2, according to a summary by IntuitionLabs.
  • Several articles cite more than 173 programmes in clinical development. We could not find where that number comes from.

Insilico alone reports 13 clearances to begin human testing and 8 ongoing Phase 1 trials in its July 2026 release.

Methodology

Phase, status, start date and enrolment were read from the ClinicalTrials.gov API on November 13, 2026, by searching each compound name and the sponsor. Inclusion follows each sponsor's own description of its platform as AI-driven. We did not verify how much of each molecule's design was done by AI. The rentosertib details are from Insilico's July 7 release, the GB-0895 claim from Generate's second-quarter update, the zasocitinib status from Takeda, and the ASCO count from IntuitionLabs. The list is not complete. This page is not medical advice.

Frequently Asked Questions

None of the compounds on this list has been approved by a regulator as of November 13, 2026. The furthest along are in Phase 3 trials that are still recruiting.
On ClinicalTrials.gov on November 13, 2026: rentosertib from Insilico Medicine for idiopathic pulmonary fibrosis (NCT07687459, 320 planned patients), and GB-0895 from Generate Biomedicines for severe asthma, in two trials of 786 planned patients each (NCT07276724 and NCT07359846).
Insilico announced the initiation of the trial on July 7, 2026. ClinicalTrials.gov lists the actual start date as September 9, 2026 and the status as recruiting. The registry estimates primary completion on October 30, 2029.
There is no agreed count. One analysis presented at ASCO in 2026 reportedly found 117 AI-enabled assets from 63 companies had entered human trials. Other articles cite more than 173. We could not trace either figure to a primary source, and the totals depend on how "AI-designed" is defined.
No trial sponsored by Isomorphic Labs appeared on ClinicalTrials.gov on November 13, 2026. The company has said it expects a first clinical trial by the end of 2026.

Hire agents, not agencies.

Presenc is a team of AI agents that builds the pages your buyers search for, and a person checks every one. We take on a few teams at a time.

Request access